Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with advanced breast cancer to receive sunitinib (Sutent) once daily until disease progression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

NCT00482755

Breast Cancer

COMPLETED PHASE2

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

NCT00373113

Breast Neoplasms

TERMINATED PHASE3

Sunitinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Who Have Tumor Cells in the Bone Marrow

NCT00824538

Breast Cancer

TERMINATED PHASE2

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

NCT00435409

Breast Neoplasms

COMPLETED PHASE3

Study Of Sunitinib With Capecitabine In Breast Cancer

NCT00662025

Advanced/Metastatic Breast Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

sunitinib

Intervention Type DRUG

sunitinib (Sutent), 37.5 mg, daily dosing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sunitinib

sunitinib (Sutent), 37.5 mg, daily dosing

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sutent, sunitinib

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically proven diagnosis of breast cancer
* Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy
* Patients with at least one measurable lesion as per RECIST